Trial · NCT00982488
Adverse events700
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 700
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diastolic dysfunction | Cardiac disorders | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | 0 | 185 | |
| other | Diastolic dysfunction | Cardiac disorders | Imatinib, 400 mg BID, Chronic Phase | 0 | 14 | |
| other | Diastolic dysfunction | Cardiac disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | 0 | 34 | |
| other | Diastolic dysfunction | Cardiac disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | 1 | 3 | |
| other | Diastolic dysfunction | Cardiac disorders | Dasatinib, 50 mg QD to 120 mg, Advanced Phase, Ph+ ALL | 0 | 1 | |
| other | Dizziness | Nervous system disorders | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | 13 | 185 | |
| other | Dizziness | Nervous system disorders | Imatinib, 400 mg BID, Chronic Phase | 0 | 14 | |
| other | Dizziness | Nervous system disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | 2 | 34 | |
| other | Dizziness | Nervous system disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | 0 | 3 | |
| other | Dizziness | Nervous system disorders | Dasatinib, 50 mg QD to 120 mg, Advanced Phase, Ph+ ALL | 0 | 1 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | 2 | 185 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Imatinib, 400 mg BID, Chronic Phase | 1 | 14 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | 0 | 34 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | 0 | 3 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Dasatinib, 50 mg QD to 120 mg, Advanced Phase, Ph+ ALL | 0 | 1 | |
| other | Insomnia | Psychiatric disorders | Dasatinib, 50 mg QD to 120 mg BID, Chronic Phase | 6 | 185 | |
| other | Insomnia | Psychiatric disorders | Imatinib, 400 mg BID, Chronic Phase | 1 | 14 | |
| other | Insomnia | Psychiatric disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, AP | 1 | 34 | |
| other | Insomnia | Psychiatric disorders | Dasatinib, 50 mg QD to 120 mg BID, Advanced Phase, MBP | 1 | 3 | |
| other | Insomnia | Psychiatric disorders | Dasatinib, 50 mg QD to 120 mg, Advanced Phase, Ph+ ALL | 0 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00982488/events